首页 | 本学科首页   官方微博 | 高级检索  
检索        

人脑胶质瘤组织中nm23与PCNA的表达及其意义
作者姓名:Tan PG  Li ZQ  Cai WQ  Lu JP  Xie FS  Weng Y
作者单位:1. 中山大学第二附属医院,神经外科,广东,广州,510120
2. 温州医学院第一附属医院,神经外科,浙江,温州,325000
3. 海南医学院病理学教研室,海南,海口,570000
摘    要:背景与目的:脑胶质瘤极少发生颅外转移,死亡的主要原因是肿瘤的原位复发,因此,通过检测基因表达进一步了解其生物学特性很重要。本研究旨在探讨胶质瘤组织中肿瘤转移抑制基因(non-metastasis,nm23)、增殖细胞核抗原(proliferatingcellnuclearantigen,PCNA)的表达及其对肿瘤恶性程度的判断、患者预后评估和复发预测的意义。方法:用免疫组化SP法测定50例不同恶性程度的胶质瘤组织中nm23、PCNA的表达情况。结果:(1)低度恶性胶质瘤标记指数(labelindex,LI)nm23为3.40±0.27,PCNA为3.60±0.05;高度恶性胶质瘤nm23LI为1.72±0.18,PCNALI为6.20±0.23,有显著性差异(P<0.05);(2)25例低度恶性胶质瘤中nm23阳性14例(56%),PCNA阳性16例(64%);而25例高度恶性胶质瘤中nm23阳性3例(12%),PCNA阳性22例(88%)。低度和高度恶性胶质瘤两组nm23、PCNA表达阳性率有显著性差异(P<0.05);(3)复发组9例,无nm23阳性者(0%),PCNA全部阳性(100%),未复发组8例,4例nm23阳性(50%),4例PCNA阳性(50%),两组nm23、PCNA的表达阳性率均有显著性差异(P<0.05);(4)胶质瘤nm23与PCNA的标记指数呈负相关(r=-0.5335,P<0.001)。结论:(1)nm23的表达随胶质瘤恶性程度增加而下降;(2)PCNA的表达随胶质瘤恶性程度的增加而升高;(3)nm23、PCNA可作为胶质瘤恶

关 键 词:人脑胶质瘤  nm23  PCNA  复发  肿瘤转移抑制基因  增殖细胞核抗原  预后
文章编号:1000-467X(2003)10-1077-04
修稿时间:2002年11月21

Expression of nm23 and proliferating cell nuclear antigen (PCNA) in human brain gliomas and their significance
Tan PG,Li ZQ,Cai WQ,Lu JP,Xie FS,Weng Y.Expression of nm23 and proliferating cell nuclear antigen (PCNA) in human brain gliomas and their significance[J].Chinese Journal of Cancer,2003,22(10):1077-1080.
Authors:Tan Ping-Guo  Li Ze-Qun  Cai Wang-Qing  Lu Jian-Ping  Xie Fu-Sheng  Weng Yang
Institution:Department of Neurosurgery, The Second Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, 510120, PR China.
Abstract:BACKGROUND & OBJECTIVE: Brain gliomas seldom undergo extracranial metastasis. Local recurrence is the main reason of tumor patient's death. Therefore, it is important to detect tumor biological features through determination of gene expression. This study was designed to investigate the expression of nm23 (non-metastasis gene, nm23)and PCNA (proliferating cell nuclear antigen) and evaluate the malignancy, recurrence, and prognosis of the tumor. METHODS: In 50 specimens of different malignant gliomas,the expression of nm23 and PCNA were examined using SP immunohistochemical staining. RESULTS: (1)The label indexes of nm23 and PCNA in low-grade gliomas were 3.40+/-0.27 and 3.60+/-0.05, respectively; while the label indexes of nm23 and PCNA in high-grade gliomas were 1.72+/-0.18 and 6.20+/-0.23, respectively.There was significant difference between the two groups(P< 0.05). (2)The positive rates of nm23 and PCNA were 56% (14 cases) and 64% (16 cases) in 25 cases of low-grade gliomas, while the positive rates of nm23 and PCNA were 12% (3 cases) and 88% (22 cases) in 25 cases of high-grade gliomas. There was significant difference between the two groups (P< 0.05). (3)The positive rates of nm23 and PCNA were 0% (0 cases) and 100% (9 cases) in 9 cases of recurrent gliomas, while the positive rates of nm23 and PCNA were 50%(34 cases) and 50%(4 cases) in 8 cases of non-recurrent gliomas. There was significant difference between the two groups (P< 0.05). (4)The label indexes of nm23 and PCNA in gliomas were inversely correlated (r=-0.5335,P< 0.001). CONCLUSION: (1)The expression of nm23 is inversely correlated with the malignancy of gliomas,i.e.the lower expression indicates the higher malignancy. (2)The expression of PCNA is associated with the increased malignancy. (3)Both nm23 and PCNA may be useful biological markers to evaluate the malignancy and prognosis of patients with gliomas.
Keywords:Glioma  nm23  Proliferating cell nuclear antigen (PCNA)  Immunohistochemistry  
本文献已被 CNKI 万方数据 PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号